The coagulation system

Journal of Neuro-Ophthalmology

Volumn 23, Issue 1, 2003, Pages 50-62

  Biousse, Valérie ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; HEPARIN COFACTOR II; PLASMINOGEN; PROCOAGULANT; PROTEIN C; PROTEIN S; THROMBOMODULIN;

ANAMNESIS; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE CLASSIFICATION; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DYSFIBRINOGENEMIA; FAMILY HISTORY; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERVISCOSITY SYNDROME; MYELOPROLIFERATIVE DISORDER; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SICKLE CELL ANEMIA; THROMBOCYTE ANOMALY; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD PLATELET DISORDERS; EYE DISEASES; HEMATOLOGIC DISEASES; HUMANS; HYPERHOMOCYSTEINEMIA; RISK FACTORS;

EID: 0037337219     PISSN: 10708022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041327-200303000-00011     Document Type: Conference Paper

References (56)

1. Biousse V. Coagulation abnormalities and their neuro-ophthalmologic manifestations. Curr Op Ophthalmol 1999;10:382-93.
2. Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997;126:638-44.
3. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood 1996;87: 3531-44.
4. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part I. Thromb Haemost 1996;76:651-62.
5. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part II. Thromb Haemost 1996;76:824-34.
6. Federman DG, Kirsner RS. An update on hypercoagulable disorders. Arch Int Med 2001;161:1051-6.
7. de Lage M, Snieder H, Ariens RA, et al. The genetic of haemostasis: a twin study. Lancet 2001;357:101-5.
8. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999;340:1555-64.
9. Edelberg JM, Christie PD, Rosenberg RD. Regulation of vascular bed-specific prothrombotic potential. Circ Res 2001;89:117-24.
10. Sykes TC, Fegan C, Mosquera D. Thrombophilia, polymorphisms, and vascular disease. Mol Pathol 2000;53:300-6.
11. Williams MS, Bray PF. Genetics of arterial prothrombotic states. Exp Biol Med 2001;226:409-19.
12. Wu AH, Tsongalis GJ. Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am J Cardiol 2001;87:1361-6.
13. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-73.
14. Bertina RM, Rosendaal FR. Venous thrombosis: the interaction of genes and environment. N Engl J Med 1998;338:1840-1.
15. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001;344:1222-31.
16. Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998;92:2353-8.
17. Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997;127:895-903.
18. De Stefano V, Chiusolo P, Paciaroni K, et al. Epidemiology of factor V Leiden: clinical implications. Sem Thromb Hemostasis 1998; 24:367-79.
19. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2817-21.
20. Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin GA20210 gene variant. Ann Intern Med 1998;129:89-93.
21. Rosendaal FR, Siscovick DS, Schwartz SM, et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-50.
22. De Stefano V, Chiusolo P, Paciaroni K, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular disease in young patients. Blood 1998;91:3562-5.
23. Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenaemias. Br J Hematol 2001;114:249-57.
24. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999;340:1021-30.
25. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91:288-94.
26. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med 1998; 339:5-11.
27. del Zoppo GJ. The role of platelets in ischemic stroke. Neurology 1998;51:S9-14.
28. Mammen EF. The sticky platelet syndrome. Sem Thromb Hemost 1999;25:361-5.
29. Vandenbroucke JP, Koster T, Briët E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
30. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344:1527-35.
31. De Bruijn SF, Stam J, Koopman MM, et al. Case control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. BMJ 1998;316: 589-92.
32. Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998;338:1793-7.
33. den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998;80:874-7.
34. Ridker PM, Manson JE, Buring JE, et al. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999;281:1817-21.
35. Brattstrom L, Wilcken DE, Ohrvik J, et al. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998;98:2520-6.
36. Selhub J, D'Angelo A. Relationship between homocysteine and thrombotic disease. Am J Med Sci 1998;316:129-41.
37. 6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998;279:359-64.
38. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449-54.
39. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999;353:1348-53.
40. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
41. Triplett DA. Antiphospholipid antibodies and thrombosis. A consequence, coincidence, or cause? Arch Pathol Lab Med 1993;117:78-88.
42. Levine SR, Salowitch-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thromboocclusive events and death: a prospective cohort study. Stroke 1997; 28:1660-5.
43. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian registry. Am J Med 1996;100:530-6.
44. Tanne D, D'Olhaberriague L, Schultz LR, et al. Anticardiolipin antibodies and their associations with cerebrovascular risk factors. Neurology 1999;52:1368-73.
45. Levine SR, Jacobs BS. 2001: a prospective, seasonal odyssey into antiphospholipid protein antibodies. Stroke 2001;32:1699-1700.
46. Tanne D, Triplett DA, Levine SR. Antiphospholipid-protein antibodies and ischemic stroke: not just cardiolipin any more. Stroke 1998;29:1755-8.
47. Brey RL, Abbott RD, Curb JD, et al. Beta2 Glycoprotein 1-dependent anticardiolipin antibodies and the risk of ischemic stroke and myocardial infarction: the honolulu heart program. Stroke 2001:32;1701-6.
48. Rosse WF. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine 1997;76:63-93.
49. Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995;333:1253-8.
50. Bick RL. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Sem Thromb Hemostasis 1998; 24:3-18.
51. Francis JL, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy. Sem Thromb Hemostasis 1998;24:93-109.
52. Mammen EF. The hematological manifestations of sepsis. J Antimicrobial Chemotherapy 1998;41(suppl A):17-24.
53. Francis JL. Laboratory investigation of hypercoagulability. Semin Thromb Hemost 1998;24:111-26.
54. McKenzie SB, Clare CN, Smith LA, et al. Laboratory test utilization in the diagnosis of hypercoagulability. Clin Lab Sci 2000;13: 215-21.
55. Quinn C, Hill J, Hassouna H. A guide for diagnosis of patients with arterial and venous thrombosis. Clin Lab Sci 2000;13:229-38.
56. Marques MB, Triplett DA. When to suspect hypercoagulability and how to investigate it. Ann Diagn Pathol 2001;5:177-83.